Active Pharmaceutical Ingredient Market Research Report: By Type of Manufacturer (Captive, Merchant), Type (Generic APIs, Innovative APIs), Type of Synthesis (Biotech, Synthetic), Type of Drug (Prescription Drugs, OTC Drugs), Therapeutic Application (Communicable Diseases, Oncology, Diabetes, Cardiovascular Diseases, Pain Management, Respiratory Diseases), Distribution Channel (Offline, Online) - Global Industry Revenue Estimation to 2030

Chapter 1. Research Background

1.1 Research Objectives

1.2 Market Definition

1.3 Analysis Period

1.4 Market Data Reporting Unit

1.4.1 Value

1.5 Market Size Breakdown by Segment

1.5.1 Market Segmentation by Type of Manufacturer

1.5.2 Market Segmentation by Type

1.5.3 Market Segmentation by Type of Synthesis

1.5.4 Market Segmentation by Type of Drug

1.5.5 Market Segmentation by Therapeutic Application

1.5.6 Market Segmentation by Distribution Channel

1.5.7 Market Segmentation by Region

1.5.8 Market Segment Analysis of Countries

1.6 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.1.1 Paid

2.1.2 Unpaid

2.1.3 P&S Intelligence Database

2.2 Primary Research

2.2.1 Breakdown of Primary Research, by Region

2.2.2 Breakdown of Primary Research, by Industry Participant

2.2.3 Breakdown of Primary Research, by Designation

2.2.4 Breakdown of Primary Research, by Company Type

2.3 Market Size Estimation

2.4 Methodology for Captive Market Size Calculation

2.5 Data Triangulation

2.6 Currency Conversion Rates

Chapter 3. Executive Summary

Chapter 4. Voice of Industry Experts/KOLs

Chapter 5. Market Indicators

5.1 World Aging Population

5.2 Global Pharmaceutical Market

5.2.1 Global Pharmaceutical Market Size

5.2.2 Global Pharmaceutical Market Breakdown, By Geography

5.2.3 Global Top 10 Selling Drugs

5.2.4 Global Pharmaceutical Market Share Analysis of Key Players (2023)

Chapter 6. Definition of Market Segments

6.1 By Type of Manufacturer

6.1.1 Captive

6.1.2 Merchant

6.2 By Type

6.2.1 Generic APIs

6.2.2 Innovative APIs

6.3 By Type of Synthesis

6.3.1 Biotech

6.3.2 Synthetic

6.4 By Type of Drug

6.4.1 Prescription Drugs

6.4.2 OTC Drugs

6.5 By Therapeutic Application

6.5.1 Oncology

6.5.2 Anti-diabetics

6.5.3 Anti-rheumatics

6.5.4 Vaccines

6.5.5 Antiviral

6.5.6 Bronchodilators

6.5.7 Sensory Organs

6.5.8 Anti-coagulants

6.5.9 Immunosuppressants

6.5.10 Dermatologicals

6.5.11 Others

6.6 By Distribution Channel

6.6.1 Offline

6.6.2 Online

Chapter 7. Industry Outlook

7.1 Market Dynamics

7.1.1 Trends

7.1.1.1 Partnerships and mergers & acquisitions

7.1.1.2 Technological advancement in API manufacturing

7.1.2 Drivers

7.1.2.1 Rising geriatric population

7.1.2.2 Increasing incidence of chronic diseases

7.1.2.3 Growing importance of generics

7.1.2.4 Impact analysis of drivers on market forecast

7.1.3 Restraints

7.1.3.1 High manufacturing costs

7.1.3.2 Unfavorable drug price control policies

7.1.3.3 Stringent regulations

7.1.3.4 Impact analysis of restraints on market forecast

7.2 Impact of COVID-19 on API Market

7.3 Porter’s Five Forces Analysis

7.3.1 Bargaining Power of Buyers

7.3.2 Bargaining Power of Suppliers

7.3.3 Intensity of Rivalry

7.3.4 Threat of New Entrants

7.3.5 Threat of Substitutes

Chapter 8. Policy and Regulatory Landscape

8.1 North America

8.2 Europe

8.3 APAC

8.4 LATAM

8.5 MEA

Chapter 9. Global Market Size and Forecast

9.1 Overview

9.2 Market Revenue, by Type of Manufacturer (2025–2030)

9.3 Market Revenue, by Type (2025–2030)

9.4 Market Revenue, by Type of Synthesis (2025–2030)

9.5 Market Revenue, by Type of Drug (2025–2030)

9.6 Market Revenue, by Therapeutic Application (2025–2030)

9.7 Market Revenue, by Distribution Channel (2025–2030)

9.8 Market Revenue, by Region (2025–2030)

Chapter 10. North America Market Size and Forecast

10.1 Overview

10.2 Market Revenue, by Type of Manufacturer (2025–2030)

10.3 Market Revenue, by Type (2025–2030)

10.4 Market Revenue, by Type of Synthesis (2025–2030)

10.5 Market Revenue, by Type of Drug (2025–2030)

10.6 Market Revenue, by Therapeutic Application (2025–2030)

10.7 Market Revenue, by Distribution Channel (2025–2030)

10.8 Market Revenue, by Country (2025–2030)

Chapter 11. Europe Market Size and Forecast

11.1 Overview

11.2 Market Revenue, by Type of Manufacturer (2025–2030)

11.3 Market Revenue, by Type (2025–2030)

11.4 Market Revenue, by Type of Synthesis (2025–2030)

11.5 Market Revenue, by Type of Drug (2025–2030)

11.6 Market Revenue, by Therapeutic Application (2025–2030)

11.7 Market Revenue, by Distribution Channel (2025–2030)

11.8 Market Revenue, by Country (2025–2030)

Chapter 12. APAC Market Size and Forecast

12.1 Overview

12.2 Market Revenue, by Type of Manufacturer (2025–2030)

12.3 Market Revenue, by Type (2025–2030)

12.4 Market Revenue, by Type of Synthesis (2025–2030)

12.5 Market Revenue, by Type of Drug (2025–2030)

12.6 Market Revenue, by Therapeutic Application (2025–2030)

12.7 Market Revenue, by Distribution Channel (2025–2030)

12.8 Market Revenue, by Country (2025–2030)

Chapter 13. LATAM Market Size and Forecast

13.1 Overview

13.2 Market Revenue, by Type of Manufacturer (2025–2030)

13.3 Market Revenue, by Type (2025–2030)

13.4 Market Revenue, by Type of Synthesis (2025–2030)

13.5 Market Revenue, by Type of Drug (2025–2030)

13.6 Market Revenue, by Therapeutic Application (2025–2030)

13.7 Market Revenue, by Distribution Channel (2025–2030)

13.8 Market Revenue, by Country (2025–2030)

Chapter 14. MEA Market Size and Forecast

14.1 Overview

14.2 Market Revenue, by Type of Manufacturer (2025–2030)

14.3 Market Revenue, by Type (2025–2030)

14.4 Market Revenue, by Type of Synthesis (2025–2030)

14.5 Market Revenue, by Type of Drug (2025–2030)

14.6 Market Revenue, by Therapeutic Application (2025–2030)

14.7 Market Revenue, by Distribution Channel (2025–2030)

14.8 Market Revenue, by Country (2025–2030)

Chapter 15. U.S. Market Size and Forecast

15.1 Overview

15.2 Market Revenue, by Type of Manufacturer (2025–2030)

15.3 Market Revenue, by Type (2025–2030)

15.4 Market Revenue, by Type of Synthesis (2025–2030)

15.5 Market Revenue, by Type of Drug (2025–2030)

15.6 Market Revenue, by Therapeutic Application (2025–2030)

15.7 Market Revenue, by Distribution Channel (2025–2030)

Chapter 16. Canada Market Size and Forecast

16.1 Overview

16.2 Market Revenue, by Type of Manufacturer (2025–2030)

16.3 Market Revenue, by Type (2025–2030)

16.4 Market Revenue, by Type of Synthesis (2025–2030)

16.5 Market Revenue, by Type of Drug (2025–2030)

16.6 Market Revenue, by Therapeutic Application (2025–2030)

16.7 Market Revenue, by Distribution Channel (2025–2030)

Chapter 17. Germany Market Size and Forecast

17.1 Overview

17.2 Market Revenue, by Type of Manufacturer (2025–2030)

17.3 Market Revenue, by Type (2025–2030)

17.4 Market Revenue, by Type of Synthesis (2025–2030)

17.5 Market Revenue, by Type of Drug (2025–2030)

17.6 Market Revenue, by Therapeutic Application (2025–2030)

17.7 Market Revenue, by Distribution Channel (2025–2030)

Chapter 18. France Market Size and Forecast

18.1 Overview

18.2 Market Revenue, by Type of Manufacturer (2025–2030)

18.3 Market Revenue, by Type (2025–2030)

18.4 Market Revenue, by Type of Synthesis (2025–2030)

18.5 Market Revenue, by Type of Drug (2025–2030)

18.6 Market Revenue, by Therapeutic Application (2025–2030)

18.7 Market Revenue, by Distribution Channel (2025–2030)

Chapter 19. U.K. Market Size and Forecast

19.1 Overview

19.2 Market Revenue, by Type of Manufacturer (2025–2030)

19.3 Market Revenue, by Type (2025–2030)

19.4 Market Revenue, by Type of Synthesis (2025–2030)

19.5 Market Revenue, by Type of Drug (2025–2030)

19.6 Market Revenue, by Therapeutic Application (2025–2030)

19.7 Market Revenue, by Distribution Channel (2025–2030)

Chapter 20. Italy Market Size and Forecast

20.1 Overview

20.2 Market Revenue, by Type of Manufacturer (2025–2030)

20.3 Market Revenue, by Type (2025–2030)

20.4 Market Revenue, by Type of Synthesis (2025–2030)

20.5 Market Revenue, by Type of Drug (2025–2030)

20.6 Market Revenue, by Therapeutic Application (2025–2030)

20.7 Market Revenue, by Distribution Channel (2025–2030)

Chapter 21. Spain Market Size and Forecast

21.1 Overview

21.2 Market Revenue, by Type of Manufacturer (2025–2030)

21.3 Market Revenue, by Type (2025–2030)

21.4 Market Revenue, by Type of Synthesis (2025–2030)

21.5 Market Revenue, by Type of Drug (2025–2030)

21.6 Market Revenue, by Therapeutic Application (2025–2030)

21.7 Market Revenue, by Distribution Channel (2025–2030)

Chapter 22. Japan Market Size and Forecast

22.1 Overview

22.2 Market Revenue, by Type of Manufacturer (2025–2030)

22.3 Market Revenue, by Type (2025–2030)

22.4 Market Revenue, by Type of Synthesis (2025–2030)

22.5 Market Revenue, by Type of Drug (2025–2030)

22.6 Market Revenue, by Therapeutic Application (2025–2030)

22.7 Market Revenue, by Distribution Channel (2025–2030)

Chapter 23. China Market Size and Forecast

23.1 Overview

23.2 Market Revenue, by Type of Manufacturer (2025–2030)

23.3 Market Revenue, by Type (2025–2030)

23.4 Market Revenue, by Type of Synthesis (2025–2030)

23.5 Market Revenue, by Type of Drug (2025–2030)

23.6 Market Revenue, by Therapeutic Application (2025–2030)

23.7 Market Revenue, by Distribution Channel (2025–2030)

Chapter 24. India Market Size and Forecast

24.1 Overview

24.2 Market Revenue, by Type of Manufacturer (2025–2030)

24.3 Market Revenue, by Type (2025–2030)

24.4 Market Revenue, by Type of Synthesis (2025–2030)

24.5 Market Revenue, by Type of Drug (2025–2030)

24.6 Market Revenue, by Therapeutic Application (2025–2030)

24.7 Market Revenue, by Distribution Channel (2025–2030)

Chapter 25. Australia Market Size and Forecast

25.1 Overview

25.2 Market Revenue, by Type of Manufacturer (2025–2030)

25.3 Market Revenue, by Type (2025–2030)

25.4 Market Revenue, by Type of Synthesis (2025–2030)

25.5 Market Revenue, by Type of Drug (2025–2030)

25.6 Market Revenue, by Therapeutic Application (2025–2030)

25.7 Market Revenue, by Distribution Channel (2025–2030)

Chapter 26. South Korea Market Size and Forecast

26.1 Overview

26.2 Market Revenue, by Type of Manufacturer (2025–2030)

26.3 Market Revenue, by Type (2025–2030)

26.4 Market Revenue, by Type of Synthesis (2025–2030)

26.5 Market Revenue, by Type of Drug (2025–2030)

26.6 Market Revenue, by Therapeutic Application (2025–2030)

26.7 Market Revenue, by Distribution Channel (2025–2030)

Chapter 27. Brazil Market Size and Forecast

27.1 Overview

27.2 Market Revenue, by Type of Manufacturer (2025–2030)

27.3 Market Revenue, by Type (2025–2030)

27.4 Market Revenue, by Type of Synthesis (2025–2030)

27.5 Market Revenue, by Type of Drug (2025–2030)

27.6 Market Revenue, by Therapeutic Application (2025–2030)

27.7 Market Revenue, by Distribution Channel (2025–2030)

Chapter 28. Mexico Market Size and Forecast

28.1 Overview

28.2 Market Revenue, by Type of Manufacturer (2025–2030)

28.3 Market Revenue, by Type (2025–2030)

28.4 Market Revenue, by Type of Synthesis (2025–2030)

28.5 Market Revenue, by Type of Drug (2025–2030)

28.6 Market Revenue, by Therapeutic Application (2025–2030)

28.7 Market Revenue, by Distribution Channel (2025–2030)

Chapter 29. Saudi Arabia Market Size and Forecast

29.1 Overview

29.2 Market Revenue, by Type of Manufacturer (2025–2030)

29.3 Market Revenue, by Type (2025–2030)

29.4 Market Revenue, by Type of Synthesis (2025–2030)

29.5 Market Revenue, by Type of Drug (2025–2030)

29.6 Market Revenue, by Therapeutic Application (2025–2030)

29.7 Market Revenue, by Distribution Channel (2025–2030)

Chapter 30. U.A.E. Market Size and Forecast

30.1 Overview

30.2 Market Revenue, by Type of Manufacturer (2025–2030)

30.3 Market Revenue, by Type (2025–2030)

30.4 Market Revenue, by Type of Synthesis (2025–2030)

30.5 Market Revenue, by Type of Drug (2025–2030)

30.6 Market Revenue, by Therapeutic Application (2025–2030)

30.7 Market Revenue, by Distribution Channel (2025–2030)

Chapter 31. Competitive Landscape

31.1 Major API Molecules

31.2 Revenue Comparison of Major Players

31.3 Global Strategic Developments

31.3.1 Partnerships

31.3.2 Product Launches and Expansion

31.3.3 Mergers & Acquisitions

Chapter 32. Company Profiles

32.1 Cipla Ltd.

32.1.1 Business Overview

32.1.2 Product and Service Offerings

32.1.3 Key Financial Summary

32.2 Dr. Reddy’s Laboratories Ltd.

32.2.1 Business Overview

32.2.2 Product and Service Offerings

32.2.3 Key Financial Summary

32.3 Teva Pharmaceutical Industries Limited

32.3.1 Business Overview

32.3.2 Product and Service Offerings

32.3.3 Key Financial Summary

32.4 Aurobindo Pharma Limited

32.4.1 Business Overview

32.4.2 Product and Service Offerings

32.4.3 Key Financial Summary

32.5 Novartis AG

32.5.1 Business Overview

32.5.2 Product and Service Offerings

32.5.3 Key Financial Summary

32.6 Pfizer Inc.

32.6.1 Business Overview

32.6.2 Product and Service Offerings

32.6.3 Key Financial Summary

32.7 Bristol-Myers Squibb Company

32.7.1 Business Overview

32.7.2 Product and Service Offerings

32.7.3 Key Financial Summary

32.8 Glenmark Life Sciences Limited

32.8.1 Business Overview

32.8.2 Product and Service Offerings

32.8.3 Key Financial Summary

32.9 Johnson & Johnson

32.9.1 Business Overview

32.9.2 Product and Service Offerings

32.9.3 Key Financial Summary

32.10 Merck & Co. Inc.

32.10.1 Business Overview

32.10.2 Product and Service Offerings

32.10.3 Key Financial Summary

32.11 AbbVie Inc.

32.11.1 Business Overview

32.11.2 Product and Service Offerings

32.11.3 Key Financial Summary

32.12 Eli Lilly and Company

32.12.1 Business Overview

32.12.2 Product and Service Offerings

32.12.3 Key Financial Summary

32.13 GlaxoSmithKline plc

32.13.1 Business Overview

32.13.2 Product and Service Offerings

32.13.3 Key Financial Summary

32.14 Sanofi

32.14.1 Business Overview

32.14.2 Product and Service Offerings

32.14.3 Key Financial Summary

32.15 Takeda Pharmaceutical Company Limited

32.15.1 Business Overview

32.15.2 Product and Service Offerings

32.15.3 Key Financial Summary

32.16 Amneal Pharmaceuticals Inc.

32.16.1 Business Overview

32.16.2 Product and Service Offerings

32.16.3 Key Financial Summary

32.17 AstraZeneca plc

32.17.1 Business Overview

32.17.2 Product and Service Offerings

32.17.3 Key Financial Summary

32.18 Sun Pharmaceutical Industries Ltd.

32.18.1 Business Overview

32.18.2 Product and Service Offerings

32.18.3 Key Financial Summary

32.19 Alkem Laboratories Limited

32.19.1 Business Overview

32.19.2 Product and Service Offerings

32.19.3 Key Financial Summary

32.20 Mylan N.V.

32.20.1 Business Overview

32.20.2 Product and Service Offerings

32.20.3 Key Financial Summary

32.21 Lupin Limited

32.21.1 Business Overview

32.21.2 Product and Service Offerings

32.21.3 Key Financial Summary

32.22 STADA Arzneimittel AG

32.22.1 Business Overview

32.22.2 Product and Service Offerings

32.22.3 Key Financial Summary

32.23 Mallinckrodt plc

32.23.1 Business Overview

32.23.2 Product and Service Offerings

32.23.3 Key Financial Summary

32.24 Glenmark Life Sciences Limited

32.24.1 Business Overview

32.24.2 Product and Service Offerings

32.24.3 Key Financial Summary

32.25 MSN Laboratories Pvt. Ltd.

32.25.1 Business Overview

32.25.2 Product and Service Offerings

Chapter 33. Appendix

33.1 Sources and References

33.2 Related Reports

 

LIST OF TABLES

 

TABLE 1 ANALYSIS PERIOD OF THE STUDY

TABLE 4 DRIVERS FOR THE MARKET: IMPACT ANALYSIS

TABLE 5 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS

TABLE 6 GLOBAL API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2019–2024)

TABLE 7 GLOBAL API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 8 GLOBAL API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 9 GLOBAL API MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 10 GLOBAL API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 11 GLOBAL API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 12 GLOBAL API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2019–2024)

TABLE 13 GLOBAL API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 14 GLOBAL API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 15 GLOBAL API MARKET REVENUE, BY TYPE OF DRUG, $M (2019–2024)

TABLE 16 GLOBAL API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 17 GLOBAL API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 18 GLOBAL API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2019–2024)

TABLE 19 GLOBAL API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 20 GLOBAL API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 21 GLOBAL API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 22 GLOBAL API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 23 GLOBAL API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 24 GLOBAL API MARKET REVENUE, BY REGION, $M (2019–2024)

TABLE 25 GLOBAL API MARKET REVENUE, BY REGION, $M (2025–2030)

TABLE 26 GLOBAL API MARKET REVENUE, BY REGION, $M (2025–2030)

TABLE 27 NORTH AMERICA API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2019–2024)

TABLE 28 NORTH AMERICA API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 29 NORTH AMERICA API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 30 NORTH AMERICA API MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 31 NORTH AMERICA API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 32 NORTH AMERICA API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 33 NORTH AMERICA API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2019–2024)

TABLE 34 NORTH AMERICA API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 35 NORTH AMERICA API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 36 NORTH AMERICA API MARKET REVENUE, BY TYPE OF DRUG, $M (2019–2024)

TABLE 37 NORTH AMERICA API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 38 NORTH AMERICA API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 39 NORTH AMERICA API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2019–2024)

TABLE 40 NORTH AMERICA API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 41 NORTH AMERICA API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 42 NORTH AMERICA API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 43 NORTH AMERICA API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 44 NORTH AMERICA API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 45 NORTH AMERICA API MARKET REVENUE, BY COUNTRY, $M (2019–2024)

TABLE 46 NORTH AMERICA API MARKET REVENUE, BY COUNTRY, $M (2025–2030)

TABLE 47 NORTH AMERICA API MARKET REVENUE, BY COUNTRY, $M (2025–2030)

TABLE 48 EUROPE API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2019–2024)

TABLE 49 EUROPE API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 50 EUROPE API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 51 EUROPE API MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 52 EUROPE API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 53 EUROPE API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 54 EUROPE API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2019–2024)

TABLE 55 EUROPE API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 56 EUROPE API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 57 EUROPE API MARKET REVENUE, BY TYPE OF DRUG, $M (2019–2024)

TABLE 58 EUROPE API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 59 EUROPE API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 60 EUROPE API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2019–2024)

TABLE 61 EUROPE API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 62 EUROPE API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 63 EUROPE API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 64 EUROPE API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 65 EUROPE API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 66 EUROPE API MARKET REVENUE, BY COUNTRY, $M (2019–2024)

TABLE 67 EUROPE API MARKET REVENUE, BY COUNTRY, $M (2025–2030)

TABLE 68 EUROPE API MARKET REVENUE, BY COUNTRY, $M (2025–2030)

TABLE 69 APAC API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2019–2024)

TABLE 70 APAC API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 71 APAC API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 72 APAC API MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 73 APAC API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 74 APAC API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 75 APAC API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2019–2024)

TABLE 76 APAC API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 77 APAC API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 78 APAC API MARKET REVENUE, BY TYPE OF DRUG, $M (2019–2024)

TABLE 79 APAC API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 80 APAC API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 81 APAC API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2019–2024)

TABLE 82 APAC API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 83 APAC API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 84 APAC API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 85 APAC API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 86 APAC API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 87 APAC API MARKET REVENUE, BY COUNTRY, $M (2019–2024)

TABLE 88 APAC API MARKET REVENUE, BY COUNTRY, $M (2025–2030)

TABLE 89 APAC API MARKET REVENUE, BY COUNTRY, $M (2025–2030)

TABLE 90 LATAM API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2019–2024)

TABLE 91 LATAM API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 92 LATAM API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 93 LATAM API MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 94 LATAM API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 95 LATAM API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 96 LATAM API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2019–2024)

TABLE 97 LATAM API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 98 LATAM API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 99 LATAM API MARKET REVENUE, BY TYPE OF DRUG, $M (2019–2024)

TABLE 100 LATAM API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 101 LATAM API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 102 LATAM API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2019–2024)

TABLE 103 LATAM API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 104 LATAM API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 105 LATAM API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 106 LATAM API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 107 LATAM API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 108 LATAM API MARKET REVENUE, BY COUNTRY, $M (2019–2024)

TABLE 109 LATAM API MARKET REVENUE, BY COUNTRY, $M (2025–2030)

TABLE 110 LATAM API MARKET REVENUE, BY COUNTRY, $M (2025–2030)

TABLE 111 MEA API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2019–2024)

TABLE 112 MEA API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 113 MEA API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 114 MEA API MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 115 MEA API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 116 MEA API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 117 MEA API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2019–2024)

TABLE 118 MEA API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 119 MEA API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 120 MEA API MARKET REVENUE, BY TYPE OF DRUG, $M (2019–2024)

TABLE 121 MEA API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 122 MEA API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 123 MEA API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2019–2024)

TABLE 124 MEA API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 125 MEA API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 126 MEA API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 127 MEA API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 128 MEA API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 129 MEA API MARKET REVENUE, BY COUNTRY, $M (2019–2024)

TABLE 130 MEA API MARKET REVENUE, BY COUNTRY, $M (2025–2030)

TABLE 131 MEA API MARKET REVENUE, BY COUNTRY, $M (2025–2030)

TABLE 132 U.S API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2019–2024)

TABLE 133 U.S. API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 134 U.S. API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 135 U.S. API MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 136 U.S. API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 137 U.S. API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 138 U.S. API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2019–2024)

TABLE 139 U.S. API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 140 U.S. API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 141 U.S. API MARKET REVENUE, BY TYPE OF DRUG, $M (2019–2024)

TABLE 142 U.S. API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 143 U.S. API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 144 U.S. API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2019–2024)

TABLE 145 U.S. API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 146 U.S. API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 147 U.S. API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 148 U.S. API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 149 U.S. API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 150 CANADA API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2019–2024)

TABLE 151 CANADA API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 152 CANADA API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 153 CANADA API MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 154 CANADA API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 155 CANADA API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 156 CANADA API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2019–2024)

TABLE 157 CANADA API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 158 CANADA API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 159 CANADA API MARKET REVENUE, BY TYPE OF DRUG, $M (2019–2024)

TABLE 160 CANADA API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 161 CANADA API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 162 CANADA API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2019–2024)

TABLE 163 CANADA API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 164 CANADA API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 165 CANADA API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 166 CANADA API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 167 CANADA API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 168 GERMANY API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2019–2024)

TABLE 169 GERMANY API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 170 GERMANY API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 171 GERMANY API MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 172 GERMANY API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 173 GERMANY API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 174 GERMANY API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2019–2024)

TABLE 175 GERMANY API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 176 GERMANY API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 177 GERMANY API MARKET REVENUE, BY TYPE OF DRUG, $M (2019–2024)

TABLE 178 GERMANY API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 179 GERMANY API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 180 GERMANY API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2019–2024)

TABLE 181 GERMANY API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 182 GERMANY API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 183 GERMANY API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 184 GERMANY API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 185 GERMANY API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 186 FRANCE API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2019–2024)

TABLE 187 FRANCE API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 188 FRANCE API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 189 FRANCE API MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 190 FRANCE API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 191 FRANCE API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 192 FRANCE API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2019–2024)

TABLE 193 FRANCE API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 194 FRANCE API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 195 FRANCE API MARKET REVENUE, BY TYPE OF DRUG, $M (2019–2024)

TABLE 196 FRANCE API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 197 FRANCE API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 198 FRANCE API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2019–2024)

TABLE 199 FRANCE API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 200 FRANCE API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 201 FRANCE API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 202 FRANCE API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 203 FRANCE API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 204 U.K. API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2019–2024)

TABLE 205 U.K. API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 206 U.K. API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 207 U.K. API MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 208 U.K. API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 209 U.K. API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 210 U.K. API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2019–2024)

TABLE 211 U.K. API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 212 U.K. API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 213 U.K. API MARKET REVENUE, BY TYPE OF DRUG, $M (2019–2024)

TABLE 214 U.K. API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 215 U.K. API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 216 U.K. API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2019–2024)

TABLE 217 U.K. API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 218 U.K. API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 219 U.K. API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 220 U.K. API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 221 U.K. API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 222 ITALY API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2019–2024)

TABLE 223 ITALY API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 224 ITALY API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 225 ITALY API MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 226 ITALY API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 227 ITALY API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 228 ITALY API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2019–2024)

TABLE 229 ITALY API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 230 ITALY API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 231 ITALY API MARKET REVENUE, BY TYPE OF DRUG, $M (2019–2024)

TABLE 232 ITALY API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 233 ITALY API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 234 ITALY API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2019–2024)

TABLE 235 ITALY API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 236 ITALY API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 237 ITALY API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 238 ITALY API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 239 ITALY API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 240 SPAIN API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2019–2024)

TABLE 241 SPAIN API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 242 SPAIN API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 243 SPAIN API MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 244 SPAIN API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 245 SPAIN API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 246 SPAIN API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2019–2024)

TABLE 247 SPAIN API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 248 SPAIN API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 249 SPAIN API MARKET REVENUE, BY TYPE OF DRUG, $M (2019–2024)

TABLE 250 SPAIN API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 251 SPAIN API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 252 SPAIN API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2019–2024)

TABLE 253 SPAIN API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 254 SPAIN API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 255 SPAIN API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 256 SPAIN API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 257 SPAIN API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 258 JAPAN API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2019–2024)

TABLE 259 JAPAN API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 260 JAPAN API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 261 JAPAN API MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 262 JAPAN API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 263 JAPAN API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 264 JAPAN API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2019–2024)

TABLE 265 JAPAN API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 266 JAPAN API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 267 JAPAN API MARKET REVENUE, BY TYPE OF DRUG, $M (2019–2024)

TABLE 268 JAPAN API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 269 JAPAN API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 270 JAPAN API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2019–2024)

TABLE 271 JAPAN API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 272 JAPAN API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 273 JAPAN API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 274 JAPAN API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 275 JAPAN API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 276 CHINA API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2019–2024)

TABLE 277 CHINA API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 278 CHINA API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 279 CHINA API MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 280 CHINA API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 281 CHINA API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 282 CHINA API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2019–2024)

TABLE 283 CHINA API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 284 CHINA API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 285 CHINA API MARKET REVENUE, BY TYPE OF DRUG, $M (2019–2024)

TABLE 286 CHINA API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 287 CHINA API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 288 CHINA API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2019–2024)

TABLE 289 CHINA API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 290 CHINA API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 291 CHINA API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 292 CHINA API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 293 CHINA API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 294 INDIA API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2019–2024)

TABLE 295 INDIA API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 296 INDIA API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 297 INDIA API MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 298 INDIA API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 299 INDIA API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 300 INDIA API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2019–2024)

TABLE 301 INDIA API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 302 INDIA API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 303 INDIA API MARKET REVENUE, BY TYPE OF DRUG, $M (2019–2024)

TABLE 304 INDIA API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 305 INDIA API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 306 INDIA API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2019–2024)

TABLE 307 INDIA API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 308 INDIA API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 309 INDIA API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 310 INDIA API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 311 INDIA API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 312 AUSTRALIA API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2019–2024)

TABLE 313 AUSTRALIA API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 314 AUSTRALIA API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 315 AUSTRALIA API MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 316 AUSTRALIA API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 317 AUSTRALIA API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 318 AUSTRALIA API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2019–2024)

TABLE 319 AUSTRALIA API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 320 AUSTRALIA API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 321 AUSTRALIA API MARKET REVENUE, BY TYPE OF DRUG, $M (2019–2024)

TABLE 322 AUSTRALIA API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 323 AUSTRALIA API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 324 AUSTRALIA API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2019–2024)

TABLE 325 AUSTRALIA API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 326 AUSTRALIA API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 327 AUSTRALIA API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 328 AUSTRALIA API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 329 AUSTRALIA API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 330 SOUTH KOREA API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2019–2024)

TABLE 331 SOUTH KOREA API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 332 SOUTH KOREA API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 333 SOUTH KOREA API MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 334 SOUTH KOREA API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 335 SOUTH KOREA API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 336 SOUTH KOREA API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2019–2024)

TABLE 337 SOUTH KOREA API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 338 SOUTH KOREA API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 339 SOUTH KOREA API MARKET REVENUE, BY TYPE OF DRUG, $M (2019–2024)

TABLE 340 SOUTH KOREA API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 341 SOUTH KOREA API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 342 SOUTH KOREA API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2019–2024)

TABLE 343 SOUTH KOREA API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 344 SOUTH KOREA API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 345 SOUTH KOREA API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 346 SOUTH KOREA API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 347 SOUTH KOREA API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 348 BRAZIL API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2019–2024)

TABLE 349 BRAZIL API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 350 BRAZIL API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 351 BRAZIL API MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 352 BRAZIL API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 353 BRAZIL API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 354 BRAZIL API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2019–2024)

TABLE 355 BRAZIL API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 356 BRAZIL API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 357 BRAZIL API MARKET REVENUE, BY TYPE OF DRUG, $M (2019–2024)

TABLE 358 BRAZIL API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 359 BRAZIL API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 360 BRAZIL API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2019–2024)

TABLE 361 BRAZIL API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 362 BRAZIL API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 363 BRAZIL API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 364 BRAZIL API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 365 BRAZIL API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 366 MEXICO API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2019–2024)

TABLE 367 MEXICO API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 368 MEXICO API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 369 MEXICO API MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 370 MEXICO API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 371 MEXICO API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 372 MEXICO API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2019–2024)

TABLE 373 MEXICO API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 374 MEXICO API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 375 MEXICO API MARKET REVENUE, BY TYPE OF DRUG, $M (2019–2024)

TABLE 376 MEXICO API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 377 MEXICO API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 378 MEXICO API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2019–2024)

TABLE 379 MEXICO API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 380 MEXICO API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 381 MEXICO API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 382 MEXICO API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 383 MEXICO API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 384 SAUDI ARABIA API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2019–2024)

TABLE 385 SAUDI ARABIA API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 386 SAUDI ARABIA API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 387 SAUDI ARABIA API MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 388 SAUDI ARABIA API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 389 SAUDI ARABIA API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 390 SAUDI ARABIA API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2019–2024)

TABLE 391 SAUDI ARABIA API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 392 SAUDI ARABIA API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 393 SAUDI ARABIA API MARKET REVENUE, BY TYPE OF DRUG, $M (2019–2024)

TABLE 394 SAUDI ARABIA API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 395 SAUDI ARABIA API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 396 SAUDI ARABIA API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2019–2024)

TABLE 397 SAUDI ARABIA API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 398 SAUDI ARABIA API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 399 SAUDI ARABIA API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 400 SAUDI ARABIA API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 401 SAUDI ARABIA API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 402 U.A.E. API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2019–2024)

TABLE 403 U.A.E. API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 404 U.A.E. API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

TABLE 405 U.A.E. API MARKET REVENUE, BY TYPE, $M (2019–2024)

TABLE 406 U.A.E. API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 407 U.A.E. API MARKET REVENUE, BY TYPE, $M (2025–2030)

TABLE 408 U.A.E. API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2019–2024)

TABLE 409 U.A.E. API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 410 U.A.E. API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

TABLE 411 U.A.E. API MARKET REVENUE, BY TYPE OF DRUG, $M (2019–2024)

TABLE 412 U.A.E. API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 413 U.A.E. API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

TABLE 414 U.A.E. API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2019–2024)

TABLE 415 U.A.E. API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 416 U.A.E. API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

TABLE 417 U.A.E. API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 418 U.A.E. API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 419 U.A.E. API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 420 MAJOR API MOLECULES

TABLE 421 REVENUE COMPARISON OF MAJOR PLAYERS, $M (2023)

TABLE 422 CIPLA LTD. – AT A GLANCE

TABLE 423 CIPLA LTD. – KEY FINANCIAL SUMMARY

TABLE 424 DR. REDDY’S LABORATORIES LTD. – AT A GLANCE

TABLE 425 DR. REDDY’S LABORATORIES LTD. – KEY FINANCIAL SUMMARY

TABLE 426 TEVA PHARMACEUTICAL INDUSTRIES LIMITED – AT A GLANCE

TABLE 427 TEVA PHARMACEUTICAL INDUSTRIES LIMITED – KEY FINANCIAL SUMMARY

TABLE 428 AUROBINDO PHARMA LIMITED – AT A GLANCE

TABLE 429 AUROBINDO PHARMA LIMITED – KEY FINANCIAL SUMMARY

TABLE 430 NOVARTIS AG – AT A GLANCE

TABLE 431 NOVARTIS AG – KEY FINANCIAL SUMMARY

TABLE 432 PFIZER INC. – AT A GLANCE

TABLE 433 PFIZER INC. – KEY FINANCIAL SUMMARY

TABLE 434 BRISTOL-MYERS SQUIBB COMPANY – AT A GLANCE

TABLE 435 BRISTOL-MYERS SQUIBB COMPANY – KEY FINANCIAL SUMMARY

TABLE 436 GLENMARK LIFE SCIENCES LIMITED – AT A GLANCE

TABLE 437 GLENMARK LIFE SCIENCES LIMITED – KEY FINANCIAL SUMMARY

TABLE 438 JOHNSON & JOHNSON – AT A GLANCE

TABLE 439 JOHNSON & JOHNSON – KEY FINANCIAL SUMMARY

TABLE 440 MERCK & CO. INC. – AT A GLANCE

TABLE 441 MERCK & CO. INC. – KEY FINANCIAL SUMMARY

TABLE 442 ABBVIE INC. – AT A GLANCE

TABLE 443 ABBVIE INC. – KEY FINANCIAL SUMMARY

TABLE 444 ELI LILLY AND COMPANY – AT A GLANCE

TABLE 445 ELI LILLY AND COMPANY – KEY FINANCIAL SUMMARY

TABLE 446 GLAXOSMITHKLINE PLC – AT A GLANCE

TABLE 447 GLAXOSMITHKLINE PLC – KEY FINANCIAL SUMMARY

TABLE 448 SANOFI – AT A GLANCE

TABLE 449 SANOFI – KEY FINANCIAL SUMMARY

TABLE 450 TAKEDA PHARMACEUTICAL COMPANY LIMITED – AT A GLANCE

TABLE 452 AMNEAL PHARMACEUTICALS INC. – AT A GLANCE

TABLE 453 AMNEAL PHARMACEUTICALS INC. – KEY FINANCIAL SUMMARY

TABLE 454 ASTRAZENECA PLC – AT A GLANCE

TABLE 455 ASTRAZENECA PLC – KEY FINANCIAL SUMMARY

TABLE 456 SUN PHARMACEUTICAL INDUSTRIES LTD. – AT A GLANCE

TABLE 457 SUN PHARMACEUTICAL INDUSTRIES LTD. – KEY FINANCIAL SUMMARY

TABLE 458 ALKEM LABORATORIES LIMITED – AT A GLANCE

TABLE 459 ALKEM LABORATORIES LIMITED – KEY FINANCIAL SUMMARY

TABLE 460 MYLAN N.V. – AT A GLANCE

TABLE 461 MYLAN N.V. – KEY FINANCIAL SUMMARY

TABLE 462 LUPIN LIMITED – AT A GLANCE

TABLE 463 LUPIN LIMITED – KEY FINANCIAL SUMMARY

TABLE 464 STADA ARZNEIMITTEL AG – AT A GLANCE

TABLE 465 STADA ARZNEIMITTEL AG – KEY FINANCIAL SUMMARY

TABLE 466 MALLINCKRODT PLC – AT A GLANCE

TABLE 467 MALLINCKRODT PLC – KEY FINANCIAL SUMMARY

TABLE 468 GLENMARK LIFE SCIENCES LIMITED – AT A GLANCE

TABLE 469 GLENMARK LIFE SCIENCES LIMITED – KEY FINANCIAL SUMMARY

TABLE 470 MSN LABORATORIES PVT.LTD. – AT A GLANCE

 

LIST OF FIGURES

 

FIG 1 MARKET SIZE BREAKDOWN BY SEGMENT

FIG 2 RESEARCH METHODOLOGY

FIG 3 BREAKDOWN OF PRIMARY RESEARCH, BY REGION

FIG 4 BREAKDOWN OF PRIMARY RESEARCH, BY INDUSTRY PARTICIPANT

FIG 5 BREAKDOWN OF PRIMARY RESEARCH, BY DESIGNATION

FIG 6 BREAKDOWN OF PRIMARY RESEARCH, BY COMPANY TYPE

FIG 7 DATA TRIANGULATION APPROACH

FIG 8 CURRENCY CONVERSION RATES FOR USD (2023)

FIG 9 GLOBAL API MARKET SUMMARY

FIG 10 VOICE OF INDUSTRY EXPERTS/KOLS

FIG 11 AGING POPULATION AS PERCENTAGE OF TOTAL POPULATION IN MAJOR REGIONS (2019 AND 2050)

FIG 12 GLOBAL PHARMACEUTICAL MARKET SIZE, $B (2019 & 2024)

FIG 13 GLOBAL PHARMACEUTICAL MARKET BREAKDOWN, BY GEOGRAPHY (2019 & 2024)

TABLE 2 GLOBAL TOP 10 SELLING DRUGS, $B (2023)

TABLE 3 GLOBAL PHARMACEUTICAL MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)

FIG 11 AGING POPULATION IN MAJOR REGIONS (2000–2050)

FIG 12 BARGAINING POWER OF BUYERS

FIG 13 BARGAINING POWER OF SUPPLIERS

FIG 14 INTENSITY OF RIVALRY

FIG 15 THREAT OF NEW ENTRANTS

FIG 16 THREAT OF SUBSTITUTES

FIG 17 GLOBAL API MARKET SNAPSHOT

FIG 18 GLOBAL API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

FIG 19 GLOBAL API MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 20 GLOBAL API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

FIG 21 GLOBAL API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

FIG 22 GLOBAL API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

FIG 23 GLOBAL API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 24 WORLDWIDE MAJOR MARKETS FOR API, $M

FIG 25 NORTH AMERICA API MARKET SNAPSHOT

FIG 26 NORTH AMERICA API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

FIG 27 NORTH AMERICA API MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 28 NORTH AMERICA API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

FIG 29 NORTH AMERICA API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

FIG 30 NORTH AMERICA API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

FIG 31 NORTH AMERICA API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 32 NORTH AMERICA API MARKET REVENUE, BY COUNTRY, $M (2025–2030)

FIG 33 EUROPE API MARKET SNAPSHOT

FIG 34 EUROPE API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

FIG 35 EUROPE API MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 36 EUROPE API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

FIG 37 EUROPE API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

FIG 38 EUROPE API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

FIG 39 EUROPE API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 40 EUROPE API MARKET REVENUE, BY COUNTRY, $M (2025–2030)

FIG 41 APAC API MARKET SNAPSHOT

FIG 42 APAC API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

FIG 43 APAC API MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 44 APAC API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

FIG 45 APAC API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

FIG 46 APAC API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

FIG 47 APAC API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 48 APAC API MARKET REVENUE, BY COUNTRY, $M (2025–2030)

FIG 49 LATAM API MARKET SNAPSHOT

FIG 50 LATAM API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

FIG 51 LATAM API MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 52 LATAM API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

FIG 53 LATAM API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

FIG 54 LATAM API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

FIG 55 LATAM API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 56 LATAM API MARKET REVENUE, BY COUNTRY, $M (2025–2030)

FIG 57 MEA API MARKET SNAPSHOT

FIG 58 MEA API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

FIG 59 MEA API MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 60 MEA API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

FIG 61 MEA API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

FIG 62 MEA API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

FIG 63 MEA API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 64 MEA API MARKET REVENUE, BY COUNTRY, $M (2025–2030)

FIG 65 U.S. API MARKET SNAPSHOT

FIG 66 U.S. API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

FIG 67 U.S. API MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 68 U.S. API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

FIG 69 U.S. API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

FIG 70 U.S. API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

FIG 71 U.S. API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 72 CANADA API MARKET SNAPSHOT

FIG 73 CANADA API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

FIG 74 CANADA API MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 75 CANADA API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

FIG 76 CANADA API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

FIG 77 CANADA API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

FIG 78 CANADA API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 79 GERMANY API MARKET SNAPSHOT

FIG 80 GERMANY API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

FIG 81 GERMANY API MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 82 GERMANY API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

FIG 83 GERMANY API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

FIG 84 GERMANY API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

FIG 85 GERMANY API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 86 FRANCE API MARKET SNAPSHOT

FIG 87 FRANCE API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

FIG 88 FRANCE API MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 89 FRANCE API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

FIG 90 FRANCE API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

FIG 91 FRANCE API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

FIG 92 FRANCE API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 93 U.K. API MARKET SNAPSHOT

FIG 94 U.K. API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

FIG 95 U.K. API MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 96 U.K. API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

FIG 97 U.K. API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

FIG 98 U.K. API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

FIG 99 U.K. API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 100 ITALY API MARKET SNAPSHOT

FIG 101 ITALY API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

FIG 102 ITALY API MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 103 ITALY API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

FIG 104 ITALY API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

FIG 105 ITALY API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

FIG 106 ITALY API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 107 SPAIN API MARKET SNAPSHOT

FIG 108 SPAIN API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

FIG 109 SPAIN API MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 110 SPAIN API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

FIG 111 SPAIN API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

FIG 112 SPAIN API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

FIG 113 SPAIN API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 114 JAPAN API MARKET SNAPSHOT

FIG 115 JAPAN API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

FIG 116 JAPAN API MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 117 JAPAN API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

FIG 118 JAPAN API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

FIG 119 JAPAN API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

FIG 120 JAPAN API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 121 CHINA API MARKET SNAPSHOT

FIG 122 CHINA API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

FIG 123 CHINA API MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 124 CHINA API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

FIG 125 CHINA API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

FIG 126 CHINA API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

FIG 127 CHINA API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 128 INDIA API MARKET SNAPSHOT

FIG 129 INDIA API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

FIG 130 INDIA API MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 131 INDIA API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

FIG 132 INDIA API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

FIG 133 INDIA API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

FIG 134 INDIA API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 135 AUSTRALIA API MARKET SNAPSHOT

FIG 136 AUSTRALIA API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

FIG 137 AUSTRALIA API MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 138 AUSTRALIA API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

FIG 139 AUSTRALIA API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

FIG 140 AUSTRALIA API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

FIG 141 AUSTRALIA API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 142 SOUTH KOREA API MARKET SNAPSHOT

FIG 143 SOUTH KOREA API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

FIG 144 SOUTH KOREA API MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 145 SOUTH KOREA API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

FIG 146 SOUTH KOREA API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

FIG 147 SOUTH KOREA API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

FIG 148 SOUTH KOREA API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 149 BRAZIL API MARKET SNAPSHOT

FIG 150 BRAZIL API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

FIG 151 BRAZIL API MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 152 BRAZIL API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

FIG 153 BRAZIL API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

FIG 154 BRAZIL API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

FIG 155 BRAZIL API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 156 MEXICO API MARKET SNAPSHOT

FIG 157 MEXICO API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

FIG 158 MEXICO API MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 159 MEXICO API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

FIG 160 MEXICO API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

FIG 161 MEXICO API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

FIG 162 MEXICO API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 163 SAUDI ARABIA API MARKET SNAPSHOT

FIG 164 SAUDI ARABIA API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

FIG 165 SAUDI ARABIA API MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 166 SAUDI ARABIA API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

FIG 167 SAUDI ARABIA API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

FIG 168 SAUDI ARABIA API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

FIG 169 SAUDI ARABIA API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 170 U.A.E. API MARKET SNAPSHOT

FIG 171 U.A.E. API MARKET REVENUE, BY TYPE OF MANUFACTURER, $M (2025–2030)

FIG 172 U.A.E. API MARKET REVENUE, BY TYPE, $M (2025–2030)

FIG 173 U.A.E. API MARKET REVENUE, BY TYPE OF SYNTHESIS, $M (2025–2030)

FIG 174 U.A.E. API MARKET REVENUE, BY TYPE OF DRUG, $M (2025–2030)

FIG 175 U.A.E. API MARKET REVENUE, BY THERAPEUTIC APPLICATION, $M (2025–2030)

FIG 176 U.A.E. API MARKET REVENUE, BY DISTRIBUTION CHANNEL, $M (2025–2030)

FIG 177 CIPLA LTD. – REVENUE SPLIT BY THERAPY AND GEOGRAPHY (2023)

FIG 178 DR. REDDY’S LABORATORIES LTD. – REVENUE SPLIT BY BUSSINESS SEGMENT AND GEOGRAPHY (2023)

FIG 179 TEVA PHARMACEUTICAL INDUSTRIES LIMITED – REVENUE SPLIT BY GEOGRAPHY (2023)

FIG 180 AUROBINDO PHARMA LIMITED – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 181 NOVARTIS AG – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 182 PFIZER INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 183 BRISTOL-MYERS SQUIBB COMPANY – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 184 GLENMARK LIFE SCIENCES LIMITED – REVENUE SPLIT BY GEOGRAPHY (2023)

FIG 185 JOHNSON & JOHNSON – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 186 MERCK & CO. INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 187 ABBVIE INC. – REVENUE SPLIT BY PRODUCT CATEGORY AND GEOGRAPHY (2023)

FIG 188 ELI LILLY AND COMPANY – REVENUE SPLIT BY THERAPEUTIC AREA AND GEOGRAPHY (2023)

FIG 189 GLAXOSMITHKLINE PLC – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 190 SANOFI – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 191 TAKEDA PHARMACEUTICAL COMPANY LIMITED – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 192 AMNEAL PHARMACEUTICALS INC. – REVENUE SPLIT BY SEGMENT (2023)

FIG 193 ASTRAZENECA PLC – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 194 SUN PHARMACEUTICAL INDUSTRIES LTD. – REVENUE SPLIT BY GEOGRAPHY (2023)

FIG 195 ALKEM LABORATORIES LIMITED – REVENUE SPLIT BY GEOGRAPHY (2023)

FIG 196 MYLAN N.V. – REVENUE SPLIT BY THERAPEUTIC AREA AND GEOGRAPHY (2023)

FIG 197 LUPIN LIMITED – REVENUE SPLIT BY GEOGRAPHY (2023)

FIG 198 STADA ARZNEIMITTEL AG – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 199 MALLINCKRODT PLC – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 200 GLENMARK LIFE SCIENCES LIMITED – REVENUE SPLIT BY GEOGRAPHY (2023)